NFKBIA and breast cancer: Kang et al. investigated ability of CUR to modulate the effects of paclitaxel on breast cancer in vitro or in vivo. In the MDA-MB-231 breast cancer cell line in vitro, CUR inhibited paclitaxel-induced NF-κB activation by blocking degradation of IκBα, and potentiated the antiproliferative effect of paclitaxel by enhancing induction of apoptosis.